Drugs A - Z

methotrexate Images

Generic Name: methotrexate

Brand Names: Trexall, Rheumatrex, Rheumatrex Dose Pack, Rasuvo, Methotrexate Sodium, Preservative Free, Otrexup, Methotrexate Lpf Sodium

There is an FDA Alert for this drug. Click here to view it.

    Experience of Supervising Clinician
  • Administer only under supervision of qualified clinicians experienced in use of antimetabolite therapy.

    Serious Toxic Reactions (Sometimes Fatal) Possible
  • Deaths reported with use in treatment of malignancy, psoriasis, and rheumatoid arthritis.
  • Use only for treatment of life-threatening neoplastic diseases or severe, recalcitrant, disabling psoriasis or rheumatoid arthritis in patients who have not responded adequately to other forms of therapy.
  • Closely monitor patients for bone marrow, hepatic, pulmonary, or renal toxicities. (See Major Toxicities under Cautions.)
  • Inform patients of risks involved with therapy and importance of remaining under care of clinician throughout therapy.

    High-Dose Regimens
  • Use of high-dose regimens recommended for treatment of osteosarcoma requires meticulous care. (See High-Dose Methotrexate Therapy with Leucovorin Rescue and also see Osteosarcoma, under Dosage and Administration.)
  • Use of high-dose regimens for other neoplastic diseases is investigational; therapeutic advantage not established.

    Formulations or Diluents Containing Preservatives
  • Do not use formulations or diluents containing preservatives for intrathecal administration or high-dose therapy.

    Fetal/Neonatal Morbidity and Mortality
  • Fetal death and/or congenital anomalies reported. Not recommended for use in women of childbearing potential unless potential benefit clearly outweighs risks; do not use in pregnant women with psoriasis or rheumatoid arthritis. (See Contraindications and also see Fetal/Neonatal Morbidity and Mortality, under Cautions.)

    Reduced Elimination
  • Elimination reduced in patients with renal impairment, ascites, or pleural effusions. Carefully monitor for toxicity in such patients; dosage reduction or discontinuance may be required.

    Concomitant Therapy with NSAIAs
  • Unexpectedly severe, sometimes fatal, myelosuppression, aplastic anemia, and GI toxicity reported with concomitant use of methotrexate (usually at high dosages) and some NSAIAs. (See Specific Drugs under Interactions.)

  • Possible hepatotoxicity, fibrosis, and cirrhosis, generally only after prolonged use. (See Hepatic Effects under Cautions.)
  • Acute liver enzyme elevations frequently observed; usually transient and asymptomatic and do not appear predictive of subsequent hepatic disease.
  • Liver biopsy after sustained use often shows histologic changes. Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests in patients with psoriasis; periodic liver biopsies usually recommended in such patients undergoing long-term therapy.
  • Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in patients with rheumatoid arthritis.

    Pulmonary Toxicity
  • Potentially dangerous pulmonary lesions, not always reversible, may occur acutely at any time during therapy and have been reported at dosages as low as 7.5 mg weekly. Pulmonary symptoms (especially dry, nonproductive cough) may require therapy interruption and careful evaluation.

    GI Toxicity
  • Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur.

    Malignant Lymphomas
  • Malignant lymphomas (e.g., non-Hodgkin’s lymphoma) may occur in patients receiving low-dose oral therapy; such lymphomas may regress following methotrexate discontinuance and may not require cytotoxic therapy. If the lymphoma does not regress following discontinuance, institute appropriate therapy.

    Tumor Lysis Syndrome
  • May induce tumor lysis syndrome in patients with rapidly growing tumors; appropriate pharmacologic and supportive treatment may prevent or alleviate syndrome.

    Dermatologic Reactions
  • Severe, occasionally fatal skin reactions reported following single or multiple doses; reactions occurred within days of oral, IM, IV, or intrathecal administration. Recovery reported with discontinuance of therapy. (See Dermatologic and Sensitivity Reactions under Cautions.)

    Opportunistic Infections
  • Potentially fatal opportunistic infections, especially Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia.

    Concomitant Radiotherapy
  • Possible increased risk of soft tissue necrosis and osteonecrosis in patients receiving methotrexate concomitantly with radiotherapy.

The Healthline Site, its content, such as text, graphics, images, search results, and other material contained on the Healthline Site ("Content"), its services, and any information or material posted on the Healthline Site by third parties are provided for informational purposes only. None of the foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately. Please read the Terms of Service for more information regarding use of the Healthline Site.